Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features

被引:18
|
作者
Rommasi, Foad [1 ]
Nasiri, Mohammad Javad [2 ]
Mirsaeidi, Mehdi [3 ]
机构
[1] Shahid Beheshti Univ, Fac Life Sci & Biotechnol, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Sch Med, Dept Microbiol, Tehran, Iran
[3] Univ Miami, Miller Sch Med, Dept Pulm & Crit Care, Miami, FL 33136 USA
关键词
SARS-CoV-2; Pathophysiology; COVID-19; treatment; Inflammatory responses; Immunosuppressive agents; Cytokine storm; NECROSIS-FACTOR-ALPHA; CORONAVIRUS DISEASE 2019; RHEUMATOID-ARTHRITIS; CLINICAL PHARMACOKINETICS; RECEPTOR ANTAGONIST; IN-VITRO; ABSOLUTE BIOAVAILABILITY; COLCHICINE THERAPY; CYTOKINE STORM; MELATONIN;
D O I
10.1007/s11010-021-04325-9
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The novel coronavirus pandemic has emerged as one of the significant medical-health challenges of the current century. The World Health Organization has named this new virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the first detection of SARS-CoV-2 in November 2019 in Wuhan, China, physicians, researchers, and others have made it their top priority to find drugs and cures that can effectively treat patients and reduce mortality rates. The symptoms of Coronavirus Disease 2019 (COVID-19) include fever, dry cough, body aches, and anosmia. Various therapeutic compounds have been investigated and applied to mitigate the symptoms in COVID-19 patients and cure the disease. Degenerative virus analyses of the infection incidence and COVID-19 have demonstrated that SARS-CoV-2 penetrates the pulmonary alveoli's endothelial cells through Angiotensin-Converting Enzyme 2 (ACE2) receptors on the membrane, stimulates various signaling pathways and causes excessive secretion of cytokines. The continuous triggering of the innate and acquired immune system, as well as the overproduction of pro-inflammatory factors, cause a severe condition in the COVID-19 patients, which is called "cytokine storm". It can lead to acute respiratory distress syndrome (ARDS) in critical patients. Severe and critical COVID-19 cases demand oxygen therapy and mechanical ventilator support. Various drugs, including immunomodulatory and immunosuppressive agents (e.g., monoclonal antibodies (mAbs) and interleukin antagonists) have been utilized in clinical trials. However, the studies and clinical trials have documented diverging findings, which seem to be due to the differences in these drugs' possible mechanisms of action. These drugs' mechanism of action generally includes suppressing or modulating the immune system, preventing the development of cytokine storm via various signaling pathways, and enhancing the blood vessels' diameter in the lungs. In this review article, multiple medications from different drug families are discussed, and their possible mechanisms of action are also described.
引用
收藏
页码:711 / 726
页数:16
相关论文
共 50 条
  • [21] Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection
    Maryam Amini Pouya
    Seyyedeh Maryam Afshani
    Armin Salek Maghsoudi
    Shokoufeh Hassani
    Kayvan Mirnia
    DARU Journal of Pharmaceutical Sciences, 2020, 28 : 745 - 764
  • [22] The understanding of the immunopathology in COVID-19 infection
    Tascioglu, Didem
    Akkaya, Emre
    Genc, Sema
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2021, 81 (04): : 255 - 263
  • [23] The Immunopathology of COVID-19 and the Cannabis Paradigm
    Paland, Nicole
    Pechkovsky, Antonina
    Aswad, Miran
    Hamza, Haya
    Popov, Tania
    Shahar, Eduardo
    Louria-Hayon, Igal
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [24] Recent developments in the immunopathology of COVID-19
    Zhang, Huan-ping
    Sun, Yuan-li
    Wang, Yan-fen
    Yazici, Duygu
    Azkur, Dilek
    Ogulur, Ismail
    Azkur, Ahmet Kursat
    Yang, Zhao-wei
    Chen, Xiao-xue
    Zhang, Ai-Zhi
    Hu, Jia-qian
    Liu, Guang-Hui
    Akdis, Mubeccel
    Akdis, Cezmi A.
    Gao, Ya-dong
    ALLERGY, 2023, 78 (02) : 369 - 388
  • [25] The Immune Response and Immunopathology of COVID-19
    Mortaz, Esmaeil
    Tabarsi, Payam
    Varahram, Mohammad
    Folkerts, Gert
    Adcock, Ian M.
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [26] Clinical Features and Treatment of COVID-19
    Yildiz, Pinar Aysert
    Dizbay, Murat
    GAZI MEDICAL JOURNAL, 2020, 31 (2A): : 255 - 259
  • [27] Hyperinflammation Syndrome in COVID-19 Disease: Pathogenesis and Potential Immunomodulatory Agents
    Hidayat, Moulid
    Handayani, Diah
    Nurwidya, Fariz
    Andarini, Sita Laksmi
    TURKISH JOURNAL OF IMMUNOLOGY, 2021, 9 (01): : 1 - 11
  • [28] Possible therapeutic agents for COVID-19: a comprehensive review
    Elhusseiny, Khaled Mosaad
    Abd-Elhay, Fatma Abd-Elshahed
    Kamel, Mohamed Gomaa
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2020, 18 (10) : 1005 - 1019
  • [29] Immunomodulatory therapies for COVID-19
    Mathur, Poonam
    Kottilil, Shyamasundaran
    FRONTIERS IN MEDICINE, 2022, 9
  • [30] Convalescent plasma in Covid-19: Possible mechanisms of action
    Rojas, Manuel
    Rodriguez, Yhojan
    Monsalve, Diana M.
    Acosta-Ampudia, Yeny
    Camacho, Bernardo
    Esteban Gallo, Juan
    Rojas-Villarraga, Adriana
    Ramirez-Santana, Carolina
    Diaz-Coronado, Juan C.
    Manrique, Ruben
    Mantilla, Ruben D.
    Shoenfeld, Yehuda
    Anaya, Juan-Manuel
    AUTOIMMUNITY REVIEWS, 2020, 19 (07)